Is AOD-9604 Legal in Louisiana?

What AOD-9604 Actually Is

AOD-9604 is a 16-amino-acid synthetic peptide corresponding to positions 176 to 191 of the human growth hormone sequence. Researchers initially investigated it for fat metabolism, theorizing that this C-terminal fragment retained the lipolytic activity of full-length hGH without the insulin-desensitizing effects associated with the intact molecule. Early animal data were encouraging, and Metabolic Pharmaceuticals (Melbourne, Australia) advanced the compound into human trials between 2001 and 2004.

The Clinical Trial Record

The completed phase II program, registered under early Australian clinical trial frameworks and later cross-referenced in the NIH database, evaluated oral and injectable formulations of AOD-9604 for weight reduction. Published findings showed no statistically significant difference in weight loss versus placebo at the doses tested in the phase II program, and the company did not file a New Drug Application (NDA) with the FDA [1]. That absence of an approved NDA is the single most consequential fact for any discussion of legality in the United States.

Why the Peptide Attracts Clinical Interest Despite the Trial Outcome

Practitioners who prescribe AOD-9604 today cite in-vitro and animal-model data showing activity at beta-3 adrenergic receptors and effects on lipolysis independent of IGF-1 pathways [2]. The compound does not appear in the DEA's Controlled Substances Act schedules, which is why it sometimes gets described as "unregulated." Unscheduled is not the same as approved or unrestricted.

The Federal Regulatory Framework That Controls AOD-9604

Understanding Louisiana-specific rules requires first understanding the federal layer, because federal law preempts state law whenever the two conflict under the Supremacy Clause.

FDA Drug Approval and the NDA Requirement

The Federal Food, Drug, and Cosmetic Act (FD&C Act) requires that any drug marketed in interstate commerce either hold an approved NDA or meet a specific statutory exemption [3]. AOD-9604 holds no approved NDA and is not listed as a generally recognized as safe and effective (GRASE) substance. Selling it as a finished drug product for human use is therefore prohibited under 21 U.S.C. 355 without an exemption.

The 503A Compounding Exemption

Section 503A of the FD&C Act, added by the Food and Drug Administration Modernization Act of 1997, allows state-licensed pharmacies to compound drugs for individual patients on the basis of a valid prescription without needing a full NDA, provided the compounded preparation is not "essentially a copy" of an approved drug, is compounded by a licensed pharmacist or physician, and does not use bulk drug substances that FDA has placed on a "negative list" [4].

The critical 2023 and 2024 FDA actions placed multiple bulk peptides under intensified scrutiny. FDA's Interim Policy on Compounding Using Bulk Drug Substances and subsequent guidance documents identified peptides including BPC-157, TB-500, and others as substances that lack the clinical evidence needed to remain available to 503A compounders without formal nomination and review [5]. AOD-9604 was explicitly referenced in FDA communications to compounding trade groups as a substance whose bulk-drug use is not currently covered by any positive determination.

The 503B Outsourcing Facility Pathway

Section 503B, added by the Drug Quality and Security Act of 2013, created a category of registered outsourcing facilities that can produce large batches without patient-specific prescriptions but must comply with current Good Manufacturing Practice (cGMP) standards and may only use bulk drug substances on FDA's 503B bulks list [6]. AOD-9604 does not appear on the 503B positive bulks list. Outsourcing facilities therefore cannot legally compound it for distribution.

Louisiana State Law Layer

Louisiana does not have a state statute that independently schedules or bans AOD-9604. The Louisiana Uniform Controlled Dangerous Substances Law (RS 40:961 et seq.) adopts schedules I through V that substantially mirror federal DEA scheduling [7]. Because AOD-9604 appears in none of those schedules, it is not a controlled dangerous substance under Louisiana law.

Louisiana Board of Pharmacy Rules

The Louisiana Board of Pharmacy regulates compounding pharmacies under the Louisiana Pharmacy Practice Act (RS 37:1161 et seq.) and adopts the USP compounding standards by reference. Louisiana 503A-equivalent pharmacies must comply with USP Chapters 795 and 797 for non-sterile and sterile preparations respectively. A compounding pharmacy in Louisiana choosing to prepare an injectable peptide like AOD-9604 must use a bulk substance that is either on FDA's 503A positive list or has been the subject of a formal nomination finding [8].

What a Louisiana Physician Can and Cannot Do

A physician licensed by the Louisiana State Board of Medical Examiners may prescribe compounded AOD-9604 for an individual patient if that physician documents a specific medical need that cannot be met by an FDA-approved alternative. This is the standard "office-use" exception recognized in Louisiana's medical practice regulations and mirrored in FDA's enforcement discretion policy. The physician takes on clinical and legal risk whenever prescribing a substance outside its approved indication or without NDA backing, and that risk increased after FDA's 2023 to 2024 peptide guidance.

Louisiana Does Not Have Its Own Peptide Prohibition

Some states (notably Florida in 2023) enacted sport-supplement or anti-doping statutes that touch on peptides. Louisiana has no equivalent statute as of the date of this article's last review. The absence of a state prohibition does not make AOD-9604 federally permissible; it simply means there is no additional state-level barrier layered on top of federal constraints.

The FDA's 2023 to 2025 Enforcement Trajectory

The FDA's posture on compounded peptides has become more restrictive year over year. In January 2024, FDA issued a final guidance clarifying that bulk drug substances used in compounding must meet the criteria in 503A(b)(1)(A)(i), and that agency inaction on a nomination does not confer permission to compound [5]. The agency has issued warning letters to compounding facilities distributing BPC-157, Selank, and Epithalon, and industry legal analysts broadly expect AOD-9604 to receive similar scrutiny.

What Enforcement Has Looked Like in Practice

FDA warning letters to compounders in 2022 and 2023 cited violations of 21 U.S.C. 353a for preparing bulk-drug-substance compounds without meeting the statutory criteria [9]. No Louisiana-specific enforcement action targeting AOD-9604 has been made public as of mid-2025, but federal enforcement jurisdiction applies equally to all states.

Impact on Telehealth Prescribers

Telehealth platforms that prescribe compounded AOD-9604 to Louisiana residents operate under the same federal constraints as brick-and-mortar practices. The DEA's 2023 telemedicine rules (finalized under 21 U.S.C. 802) require an in-person medical evaluation or a qualifying telemedicine exception for controlled substances, but AOD-9604 is not a controlled substance, so that specific rule does not apply [10]. Practitioners still bear responsibility for ensuring the compounding pharmacy they direct patients to operates within 503A requirements.

How Patients in Louisiana Currently Access AOD-9604

The Compounding Pharmacy Prescription Route

The only legally defensible access pathway for a Louisiana resident is a patient-specific prescription from a Louisiana-licensed physician sent to a 503A-compliant compounding pharmacy. The pharmacy must verify it has documentation supporting the use of AOD-9604 as a bulk substance, which, given the FDA's current guidance, means the prescriber must provide individualized clinical justification in writing. This is not a rubber-stamp process.

Research Use

Institutions conducting IRB-approved research may obtain AOD-9604 from chemical suppliers under an IND (Investigational New Drug) application filed with the FDA under 21 CFR Part 312 [11]. This pathway is not available to individual patients outside a formal trial.

What Is Not Legal

Purchasing AOD-9604 labeled "for research use only" from a domestic or overseas supplier and self-administering it is not a legal gray area. It is a violation of 21 U.S.C. 331(d), which prohibits introduction into interstate commerce of any new drug for which no NDA is approved. Louisiana residents are not exempt from this federal prohibition.

Importing AOD-9604 from a foreign pharmacy without FDA authorization constitutes importation of an unapproved drug under 21 U.S.C. 381, regardless of whether the sending country considers the compound legal [12].

Clinical Risk Context: Why the Legal Framework Matters

The regulatory restrictions on AOD-9604 exist partly because the clinical evidence base is thin. The 2001 to 2004 phase II program did not demonstrate efficacy for weight loss at the doses tested, and no phase III data exist [1]. Without phase III efficacy and safety data, FDA cannot make a benefit-risk determination sufficient for NDA approval.

Safety Data Gaps

Injectable peptides prepared by compounding pharmacies are sterile preparations under USP 797 standards. Quality control failures in compounding have caused serious harm in the past: a 2012 fungal meningitis outbreak linked to contaminated compounded methylprednisolone acetate killed 64 people and sickened 753, prompting the Drug Quality and Security Act that created 503B [13]. This history informs why FDA scrutinizes bulk-drug-substance compounding.

IGF-1 and Growth Hormone Axis Considerations

AOD-9604 is often marketed as growth-hormone-fragment therapy that does not raise IGF-1. The available in-vitro data support a relative selectivity for lipolytic pathways over IGF-1 stimulation [2]. Clinicians should still assess baseline IGF-1, fasting glucose, and lipid panels before initiating any growth-hormone-pathway peptide, because individual receptor sensitivity varies and long-duration effects in humans remain unstudied beyond the four-year follow-up in the Australian phase II program.

Comparing AOD-9604 to Approved Alternatives

For patients seeking weight management support in Louisiana, two FDA-approved options have substantially stronger evidence: semaglutide 2.4 mg (Wegovy) and tirzepatide 15 mg (Zepbound). In the STEP-1 trial (N=1,961), semaglutide 2.4 mg produced 14.9% mean weight loss at 68 weeks versus 2.4% for placebo (P<0.001) [14]. In the SURMOUNT-1 trial (N=2,539), tirzepatide 15 mg produced 20.9% mean weight loss at 72 weeks versus 3.1% for placebo (P<0.001) [15].

AOD-9604 has no comparable phase III weight-loss dataset. Patients and clinicians weighing the two approaches should factor in both the legal stability of the approved agents and the magnitude of the evidence base.

Practical Guidance for Louisiana Patients

A Louisiana resident who wants to pursue AOD-9604 should take these concrete steps before spending money or assuming legality.

First, request a consultation with a physician licensed by the Louisiana State Board of Medical Examiners who is familiar with compounding law and the FDA's current peptide guidance. Ask the physician specifically whether the compounding pharmacy they use has received any FDA inspection findings related to peptides.

Second, ask the compounding pharmacy directly whether it has a documented pathway for AOD-9604 under 503A and whether it can provide a Certificate of Analysis (CoA) from an ISO-accredited third-party lab for each batch. No CoA means no verified purity or potency.

Third, review FDA's publicly posted 503A bulks database, which is updated periodically, before assuming the compound's status has not changed since this article was written [5].

Any Louisiana physician prescribing AOD-9604 should document the individualized clinical rationale, confirm the pharmacy's compliance status, and inform the patient in writing that the compound is not FDA-approved and that the long-term safety data in humans are limited to a four-year window from a single phase II program.